Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma - PubMed (original) (raw)
Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma
Ashok Raj et al. J Hepatol. 2011 Nov.
Abstract
Background & aims: The "Metroticket" prognostic model for survival post liver transplant for hepatocellular carcinoma (HCC) was developed from a European cohort of patients with predominantly alcoholic liver disease and hepatitis C-related HCC. The aim of this study was to evaluate the prognostic value of the Metroticket in an independent cohort of patients with predominantly HBV-related HCC, in an Asia-Pacific transplant programme.
Methods: All patients listed for HCC at the New Zealand Liver Transplant Unit (NZLTU) between January 1998 and November 2009 were included. For each patient, the predicted 3 and 5 year post-transplant survival score was calculated using the Metroticket model (http://www.hcc-oltmetroticket.org/calculator/index.php). The observed and predicted survivals were compared.
Results: Ninety-five patients with HCC were listed, 82 were transplanted (40 with HBV) and 13 delisted for progression. Predicted survival calculated by the Metroticket model based on pre-transplant radiological data (n = 82) was 76.3% and 69.7% at 3 and 5 years, respectively, while the observed survival was 83% (49/59) and 74% (35/47), respectively. Of the 40 patients with HBV, observed survivals were 84% (26/31) and 80% (20/25) at 3 and 5 years, compared with 80% (23/28) and 69.6% (16/23), respectively, for the 42 patients without HBV. On intent to treat analysis, survival after listing was 73.8% (95% CI 62.7-82.1) at 3 years and 69.1% (53.7-78.2%) at 5 years. AFP level was associated with vascular invasion.
Conclusions: The Metroticket calculator incorporating pre-transplant radiological Staging was an accurate predictor of post-transplant survival in a cohort of predominantly HBV-related HCC.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
- Validation of the "Metroticket" model in a cohort of patients transplanted for hepatocellular carcinoma in southern Brazil.
Machado A, Kiss G, Ernani L, Marroni C, Zanotelli ML, Cantisani G, Cerski CT, Coral G, Brandão A; Liver Transplantation Group. Machado A, et al. Clin Transplant. 2015 Sep;29(9):806-12. doi: 10.1111/ctr.12583. Epub 2015 Jul 23. Clin Transplant. 2015. PMID: 26119109 - Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators.
Bhattacharjya S, Bhattacharjya T, Quaglia A, Dhillon AP, Burroughs AK, Patch DW, Tibballs JM, Watkinson AF, Rolles K, Davidson BR. Bhattacharjya S, et al. Dig Surg. 2004;21(2):152-9; discussion 159-60. doi: 10.1159/000078741. Epub 2004 May 27. Dig Surg. 2004. PMID: 15166485 - Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A. Mazzaferro V, et al. Gastroenterology. 2018 Jan;154(1):128-139. doi: 10.1053/j.gastro.2017.09.025. Epub 2017 Oct 5. Gastroenterology. 2018. PMID: 28989060 - LI-RADS and transplantation for hepatocellular carcinoma.
Tang A, Fowler KJ, Chernyak V, Chapman WC, Sirlin CB. Tang A, et al. Abdom Radiol (NY). 2018 Jan;43(1):193-202. doi: 10.1007/s00261-017-1210-8. Abdom Radiol (NY). 2018. PMID: 28612162 Review. - Assessment of treatment response in hepatocellular carcinoma: a review of the literature.
Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Maida M, et al. Future Oncol. 2013 Jun;9(6):845-54. doi: 10.2217/fon.13.33. Future Oncol. 2013. PMID: 23718305 Review.
Cited by
- Hepatocellular carcinoma: A comprehensive review.
Waller LP, Deshpande V, Pyrsopoulos N. Waller LP, et al. World J Hepatol. 2015 Nov 18;7(26):2648-63. doi: 10.4254/wjh.v7.i26.2648. World J Hepatol. 2015. PMID: 26609342 Free PMC article. Review. - An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.
Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. Miao W, et al. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3656-3665. doi: 10.1007/s00259-021-05328-w. Epub 2021 Apr 4. Eur J Nucl Med Mol Imaging. 2021. PMID: 33813592 - Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics.
Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Lai Q, et al. Cancers (Basel). 2019 Oct 15;11(10):1568. doi: 10.3390/cancers11101568. Cancers (Basel). 2019. PMID: 31618961 Free PMC article. Review. - Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Meischl T, et al. United European Gastroenterol J. 2021 Mar;9(2):209-219. doi: 10.1177/2050640620948665. Epub 2021 Feb 10. United European Gastroenterol J. 2021. PMID: 32741316 Free PMC article. - Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach.
Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Biolato M, et al. World J Gastroenterol. 2017 May 14;23(18):3195-3204. doi: 10.3748/wjg.v23.i18.3195. World J Gastroenterol. 2017. PMID: 28566879 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical